Who can join
Studies for children and teens
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
468 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2/Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Merck Sharp & Dohme LLC
- Location
- Los Angeles, CA + 19 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 1/Phase 2
Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
Skylark Bio Inc.
- Location
- Bethesda, MD + 3 other US sites
- Eligibility basics
- Ages 10 mo–7
- RecruitingPhase 3
A Study of Depemokimab in Participants of 6 to 11 Years of Age
GlaxoSmithKline
- Location
- Mobile, AL + 2 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 2
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Pfizer
- Location
- New York, NY + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
OPKO Health, Inc.
- Location
- Greenville, SC
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Dothan, AL + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
Galderma R&D
- Location
- San Antonio, TX
- Eligibility basics
- Ages 6 mo–1
- RecruitingPhase 2
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Mannkind Corporation
- Location
- Los Angeles, CA + 9 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 4
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Bausch Health Americas, Inc.
- Location
- Lynwood, CA + 9 other US sites
- Eligibility basics
- Ages 6–12
- Recruiting
Brain Stimulation Paired With Structured Reading Instruction in Children With Dyslexia
General Neuro Inc.
- Location
- Boston, MA
- Eligibility basics
- Ages 7–17
- RecruitingPhase 2
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Merck Sharp & Dohme LLC
- Location
- Chicago, IL
- Eligibility basics
- Ages 0 mo–2
- RecruitingPhase 2/Phase 3
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Chiesi Farmaceutici S.p.A.
- Location
- Phoenix, AZ + 5 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
Pharmacosmos A/S
- Location
- Miami, FL
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- Tucson, AZ + 39 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Octapharma
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Takeda
- Location
- Orange, CA + 2 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
- Location
- Phoenix, AZ + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 4
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Bausch Health Americas, Inc.
- Location
- Bryant, AR + 13 other US sites
- Eligibility basics
- Ages 9–11
- RecruitingPhase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie
- Location
- Anaheim, CA + 30 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- San Francisco, CA + 3 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
QED Therapeutics, a BridgeBio company
- Location
- Oakland, CA + 2 other US sites
- Eligibility basics
- Ages 0 mo–2
- RecruitingPhase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Celgene
- Location
- New York, NY
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Merck Sharp & Dohme LLC
- Location
- Atlanta, GA
- Eligibility basics
- Ages 1 mo–11
- RecruitingPhase 2
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Pfizer
- Location
- Garden Grove, CA + 11 other US sites
- Eligibility basics
- Ages 12–17
Questions
If I fit this group, will I qualify?
Not necessarily. Age and sex limits are only the first filter. Each study has its own inclusion and exclusion criteria, and the research team decides at screening.
Where do these age and sex limits come from?
From the eligibility section of each study’s official ClinicalTrials.gov record. We don’t infer eligibility from anything else.